This Project Grant award of $433,824 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to investigate metabolic mechanisms underlying diabetic cardiomyopathy and the potential protective effects of SGLT2 inhibitors. The primary objectives are to: 1) Use induced pluripotent stem cells (iPSCs) derived from type 2 diabetes patients to generate cardiovascular cell types (cardiomyocytes, endothelial...
This $496,367 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel approaches for in situ cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing if knockdown of individual repressors can recapitulate the effects of combined knockdown. Determine if targeting the repressor complex...
This Project Grant award of $740,037, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of cardiac fibroblasts in regulating angiogenesis following myocardial infarction. The key objectives are to evaluate the function of anti-angiogenic factors like collagen type XVIII (COL18A1) in cardiac fibroblasts, and determine if the expression of pro-angiogenic factors like slit...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,408,580 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM)-associated heart failure. The primary awardee, The Leland Stanford Junior University, will conduct this research using human induced pluripotent stem cell cardiomyocytes and a mouse model of DCM. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $639,621 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of mitochondria in cardiomyocyte-fibroblast signaling and cardiac fibrosis. The key objectives are to: Investigate whether cardiomyocyte-specific expression of inactive PI3Kg regulates the release of intact...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $159,512 to Stanford University to conduct research aimed at uncovering effective strategies to mitigate the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The research will leverage human induced pluripotent stem cell-derived cardiac organoids (iPSC-COs) to validate and describe the anti-fibrotic...
This Project Grant award, totaling $1,862,169.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research, supports a comprehensive research initiative to investigate the mechanism of myocardial fibrosis induced by mitral valve prolapse (MVP). The research project, led by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to elucidate the link between altered mechanical forces caused by MVP and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,283,558 to Massachusetts Institute of Technology (MIT) to develop a breakthrough innovation in electrophysiological monitoring of cardiomyocyte networks. The key products and services to be delivered under this 4-year award include: 1) Developing a scalable nanofabrication process to manufacture multi-electroplasmonic nanoantenna...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to: 1) fully characterize at the atomic level three functional domains of the cardiac thin filament linked to the regulation of relaxation, and...
This federal Project Grant award of $717,246, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to elucidate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The primary objectives are to: Confirm cardiovascular dysfunction phenotypes in a multiple myeloma mouse model and perform single-cell RNA sequencing to identify alternative splicing events in smooth...